Connect with us

Hi, what are you looking for?

Jewish Business News


Three Way Takeover Battle: Mylan mulling improved offer for Perrigo – Bloomberg

Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders’ risk

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), Bloomberg reports.

According to Bloomberg, Mylan chairman Robert Coury has said in private conversation that his company’s management is considering improving its latest offer to Perrigo shareholders in order to reduce their risk yet further.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Coury is also reported as having told investors that he is determined to repel Teva’s bid…. [READ MORE]


Published by Globes [online], Israel business news –




Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) had an opportunity to acquire US pharmaceuticals company Perrigo Company (NYSE:PRGO; TASE:PRGO) a few months ago, and said it was not interested, sources More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

On Friday, May 8th, 2015

Three Way Takeover Battle: Mylan Chairman Tells Investors He Would Consider Buying Teva

Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd More…

John Paulson 640x360

On Wednesday, May 6th, 2015

Teva Takeover Supporter Paulson Raises Mylan Stake

John Paulson‘s hedge fund has increased its holdings in Mylan NV to 4.5%. The fund, which supports Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA; TASE: TEVA) takeover bid for Mylan, bought More…


On Tuesday, May 5th, 2015

Benny Landa: Teva Would Be Wrong to Buy Mylan

Benny Landa feels confused. The successful entrepreneur, one of the fathers of Israel’s digital printing equipment industry, does not quite understand why Israel’s Teva Pharmaceutical Industries Ltd. More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Jewish Business News Correspondent On Thursday, April 30th, 2015

Teva Sends Letter to Mylan Board: Shareholders Won’t Benefit From Mud Slinging

Mylan is using a bid for Perrigo to avoid a hostile takeover by Teva. Given sparkly valuations, it may be safer to be a seller than a buyer. April 29, 2015:  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: More…

Erez Vigodman,   Teva

On Tuesday, April 28th, 2015

“Even at $100 Per Share Teva’s Mylan Bid Worthwhile”

“Mylan Laboratories is a good acquisition target for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), and in my opinion, Teva’s shareholders will welcome it, but it also depends More…


On Tuesday, April 28th, 2015

Tamir Capital Soars After Court Ruling Against Teva

Shares in Tamir Capital are soaring on lively volumes, following a Tel Aviv District Court ruling that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) infringed the terms of a license from Proneuron More…

TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Jewish Business News Correspondent On Tuesday, April 28th, 2015

[Full Announcement] Mylan Board Unanimously Rejects Teva Bid: Low-Quality, High-Risk, Poor Record

Board concludes that approach grossly undervalues Mylan, includes Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of delivering shareholder value Proposed combination More…

Erez-Vigodman teva

On Sunday, April 26th, 2015

Teva Undeterred by Mylan Rejection

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is undeterred by the rejection of its bid for Mylan N.V. (Nasdaq: MYL). Teva president and CEO Erez Vigodman said, “While we are disappointed that More…



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.